drugset / Trial / NCT07140900
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Timeline
- Start
- 2025-10-07
- Primary completion
- 2028-03-27
- Completion
- 2030-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Subject | Darolutamide | Other / unclassified | — | Oral |
| Subject | Xaluritamig | Unknown | — | Intravenous |